Funding for this research was provided by:
the Swedish Parkinson’s Disease Foundation (NA)
The Västerbotten County Council (ALF), Sweden (NA)
Text and Data Mining valid from 2018-11-15
Received: 20 August 2018
Accepted: 17 October 2018
First Online: 15 November 2018
Ethics approval and consent to participate
: This study was approved by the regional Ethics Committee of Umeå University (registration numbers dnr 2014-364-31, 2015-394-32, 2016-300-32, and 2017-369-32) and the local radiation safety committee at the University Hospital of Umeå (registration numbers 1417, 1616, and 1717) and conducted within a registered on-going, non-profit phase II clinical trial of [<sup>18</sup>F]FE-PE2I (Eudra CT no. 2015–003045-26, the <i>PEARL-PD</i> project) approved by the Swedish Medical Products Agency (registration numbers 5.1-2015-76714, 5.1-2016-64141, and 5.12017-76924).
: All procedures performed in in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Oral and written informed consent was obtained from all individual participants included in the study.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.